MetaVia Inc MTVA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-08-05 |
| Shares Out. | 5,160,000 |
| Website | metaviatx.com/ ↗ |
| Phone | 18577029600 |
| Employees | 8 |
| Net Income | -$3.8M |
| Free Cash Flow | -$15.1M |
| Total Assets | $14.4M |
| Total Liabilities | $5.3M |
| Equity | $9.1M |
About MetaVia Inc
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
MetaVia Inc is a publicly traded company under the ticker symbol MTVA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)